| pubmed-article:20510542 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20510542 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
| pubmed-article:20510542 | lifeskim:mentions | umls-concept:C0024301 | lld:lifeskim |
| pubmed-article:20510542 | lifeskim:mentions | umls-concept:C0205101 | lld:lifeskim |
| pubmed-article:20510542 | lifeskim:mentions | umls-concept:C1134535 | lld:lifeskim |
| pubmed-article:20510542 | lifeskim:mentions | umls-concept:C2347880 | lld:lifeskim |
| pubmed-article:20510542 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:20510542 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:20510542 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20510542 | pubmed:dateCreated | 2011-2-28 | lld:pubmed |
| pubmed-article:20510542 | pubmed:abstractText | We combined external beam radiotherapy (EBRT) with yttrium-90 ibritumomab tiuxetan ((90)Y-IT) in an attempt to improve therapeutic response in patients with relapsed or refractory bulky follicular lymphoma (RRBFL). | lld:pubmed |
| pubmed-article:20510542 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20510542 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20510542 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20510542 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20510542 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20510542 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20510542 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20510542 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:20510542 | pubmed:issn | 1879-355X | lld:pubmed |
| pubmed-article:20510542 | pubmed:author | pubmed-author:ReddyChandana... | lld:pubmed |
| pubmed-article:20510542 | pubmed:author | pubmed-author:BurdickMichae... | lld:pubmed |
| pubmed-article:20510542 | pubmed:author | pubmed-author:PohlmanBradB | lld:pubmed |
| pubmed-article:20510542 | pubmed:author | pubmed-author:MacklisRogerR | lld:pubmed |
| pubmed-article:20510542 | pubmed:author | pubmed-author:NeumannDonald... | lld:pubmed |
| pubmed-article:20510542 | pubmed:author | pubmed-author:TendulkarRahu... | lld:pubmed |
| pubmed-article:20510542 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Inc. All rights reserved. | lld:pubmed |
| pubmed-article:20510542 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20510542 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:20510542 | pubmed:volume | 79 | lld:pubmed |
| pubmed-article:20510542 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20510542 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20510542 | pubmed:pagination | 1124-30 | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:meshHeading | pubmed-meshheading:20510542... | lld:pubmed |
| pubmed-article:20510542 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20510542 | pubmed:articleTitle | External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma. | lld:pubmed |
| pubmed-article:20510542 | pubmed:affiliation | Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA. | lld:pubmed |
| pubmed-article:20510542 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20510542 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:20510542 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:20510542 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
